BR112016028192A2 - gerritdina g. schoonus-gerritsma - Google Patents

gerritdina g. schoonus-gerritsma

Info

Publication number
BR112016028192A2
BR112016028192A2 BR112016028192A BR112016028192A BR112016028192A2 BR 112016028192 A2 BR112016028192 A2 BR 112016028192A2 BR 112016028192 A BR112016028192 A BR 112016028192A BR 112016028192 A BR112016028192 A BR 112016028192A BR 112016028192 A2 BR112016028192 A2 BR 112016028192A2
Authority
BR
Brazil
Prior art keywords
schoonus
gerritdin
gerritsma
relates
present
Prior art date
Application number
BR112016028192A
Other languages
English (en)
Inventor
G Schoonus-Gerritsma Gerritdina
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BR112016028192A2 publication Critical patent/BR112016028192A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Abstract

a presente invenção refere-se às formulações farmacêuticas estáveis. mais especificamente, a presente invenção refere-se às formulações farmacêuticas estáveis de undecanoato de testosterona.
BR112016028192A 2014-06-17 2015-06-15 gerritdina g. schoonus-gerritsma BR112016028192A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14172805 2014-06-17
PCT/EP2015/063292 WO2015193224A1 (en) 2014-06-17 2015-06-15 Stable formulations of testosterone undecanoate

Publications (1)

Publication Number Publication Date
BR112016028192A2 true BR112016028192A2 (pt) 2017-08-22

Family

ID=50980940

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016028192A BR112016028192A2 (pt) 2014-06-17 2015-06-15 gerritdina g. schoonus-gerritsma

Country Status (12)

Country Link
US (1) US9925200B2 (pt)
EP (1) EP3157505B1 (pt)
JP (1) JP6618488B2 (pt)
KR (1) KR20170020779A (pt)
CN (1) CN106456782B (pt)
AU (1) AU2015276321B2 (pt)
BR (1) BR112016028192A2 (pt)
CA (1) CA2950670A1 (pt)
ES (1) ES2749008T3 (pt)
MX (1) MX2016016612A (pt)
RU (1) RU2708238C2 (pt)
WO (1) WO2015193224A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019102040A1 (en) 2017-11-27 2019-05-31 Umecrine Cognition Ab PHARMACEUTICAL FORMULATION OF 3α-ETHYNYL-3β-HYDROXYANDROSTAN-17-ONE OXIME

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189235C (nl) 1974-02-28 1993-02-16 Akzo Nv Werkwijze voor de bereiding van een oraal toe te dienen farmaceutisch preparaat met androgene werking.
US4098802A (en) 1975-02-18 1978-07-04 Akzona Incorporated Oral pharmaceutical preparation having androgenic activity
US4147783A (en) 1974-02-28 1979-04-03 Akzona Incorporated Oral pharmaceutical preparation
NL7510104A (nl) 1975-08-27 1977-03-01 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat.
US5532002A (en) 1989-08-17 1996-07-02 Cortecs Limited Gelatin pharmaceutical formulations
ES2062543T3 (es) 1989-08-17 1994-12-16 Cortecs Ltd Formulaciones farmaceuticas.
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
JP2002511099A (ja) 1997-07-29 2002-04-09 ファルマシア・アンド・アップジョン・カンパニー 親油性化合物用の自己乳化性処方
US7396526B1 (en) * 1998-11-12 2008-07-08 Johnson & Johnson Consumer Companies, Inc. Skin care composition
TR200102769T2 (tr) 1999-04-01 2002-05-21 Akzo Nobel N.V. Testosteron undekanoat ve hint yağı ihtiva eden formülasyon
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
RU2303981C2 (ru) * 2000-11-01 2007-08-10 Юнимед Фармасьютикалс, Инк. Способ лечения эректильной дисфункции и повышения либидо у мужчин
AU2005309808A1 (en) * 2004-11-24 2006-06-01 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
BRPI0607549A2 (pt) 2005-04-15 2009-09-15 Clarus Therapeutics Inc sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US20130303495A1 (en) * 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
US20110160168A1 (en) * 2009-12-31 2011-06-30 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
WO2011129812A1 (en) 2010-04-12 2011-10-20 Clarus Therapeutics, Inc. Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same
US9034858B2 (en) * 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120135074A1 (en) 2010-11-30 2012-05-31 Chandrashekar Giliyar High-Strength Testosterone Undecanoate Compositions
WO2014145518A2 (en) 2013-03-15 2014-09-18 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
US10245273B2 (en) 2013-12-26 2019-04-02 Clarus Therapeutics, Inc. Oral pharmaceutical products and methods of use combining testosterone esters with hypolipidemic agents

Also Published As

Publication number Publication date
MX2016016612A (es) 2017-03-20
JP2017522283A (ja) 2017-08-10
EP3157505B1 (en) 2019-07-24
CN106456782A (zh) 2017-02-22
US20170136033A1 (en) 2017-05-18
US9925200B2 (en) 2018-03-27
JP6618488B2 (ja) 2019-12-11
RU2017101240A (ru) 2018-07-17
WO2015193224A1 (en) 2015-12-23
ES2749008T3 (es) 2020-03-18
KR20170020779A (ko) 2017-02-24
AU2015276321A1 (en) 2016-11-10
AU2015276321B2 (en) 2019-10-24
RU2708238C2 (ru) 2019-12-05
EP3157505A1 (en) 2017-04-26
RU2017101240A3 (pt) 2019-02-22
CN106456782B (zh) 2020-02-18
CA2950670A1 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
BR112017006137A2 (pt) formulação que contém biotensoativo
ZA201608209B (en) Stable cannabinoid formulations
DOP2017000298A (es) Reguladores de nrf2
CL2016002455A1 (es) Anticuerpos multiespecíficos.
BR112018006471A2 (pt) compostos úteis como moduladores de trpm8
BR112017004573A2 (pt) composições detergentes contendo um tensoativo ramificado
PH12016501151A1 (en) Nrf2 regulators
EP3302426A4 (en) D2o stabilized pharmaceutical formulations
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
GEP20217239B (en) Pharmaceutical composition
MX2015016755A (es) Reagrupamiento del virus de influenza.
BR112017027137A2 (pt) reguladores de nrf2
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
EP3099381A4 (en) Extended release fragrance compositions
TR201910057T4 (tr) Kauçuk bi̇leşi̇mleri̇
IN2013MU03641A (pt)
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
GEP20217240B (en) Pharmaceutical composition
GT201600252A (es) Derivados de naftiridinadiona
BR112017008854A2 (pt) partículas de cadotrila
IN2014CH00840A (pt)
EA201691924A1 (ru) Фармацевтические композиции
MX2016003207A (es) Composiciones que comprenden colina y derivados de esta, usos de las composiciones y procesos para su preparacion.
MX2015009330A (es) Reordenamiento del virus de influenza.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements